Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Charlotte Moira Norfor Allerton is active.

Publication


Featured researches published by Charlotte Moira Norfor Allerton.


Bioorganic & Medicinal Chemistry Letters | 2003

Design, synthesis and biological activity of β-carboline-based type-5 phosphodiesterase inhibitors

Graham Nigel Maw; Charlotte Moira Norfor Allerton; Eugene Gbekor; William A. Million

The SAR of a series of beta-carboline derived type 5 phosphodiesterase inhibitors has been explored and we have discovered compounds with excellent levels of PDE5 potency and selectivity over PDE6. However, the series exhibits low levels of selectivity over PDE11, a phosphodiesterase with unknown function.


Bioorganic & Medicinal Chemistry Letters | 2009

Design and synthesis of pyridazinone-based 5-HT2C agonists

Charlotte Moira Norfor Allerton; Mark David Andrews; Julian Blagg; David Ellis; Edel Evrard; Martin P. Green; Kevin K.-C. Liu; Gordon McMurray; Michael Ralph; Vivienne Sanderson; Lesa Watson

The SAR of a series of pyridazinone derived 5-HT(2C) agonists has been explored and resulted in identification of a compound with excellent levels of 5-HT(2C) functional agonism and selectivity over 5-HT(2A) and 5-HT(2B). This compound displayed good in vivo efficacy in pre-clinical models of stress urinary incontinence, despite having physiochemical properties commensurate with impaired CNS penetration.


Bioorganic & Medicinal Chemistry Letters | 2009

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT2c agonists

Mark David Andrews; Martin P. Green; Charlotte Moira Norfor Allerton; David V. Batchelor; Julian Blagg; Alan Daniel Brown; David W. Gordon; Gordon McMurray; Daniel J. Millns; Carly L. Nichols; Lesa Watson

This Letter reports the design and synthesis of several novel series of piperazinyl pyrimidinones as 5-HT(2C) agonists. Several of the compounds presented exhibit good in vitro potency and selectivity over the closely related 5-HT(2A) and 5-HT(2B) receptors. Compound 11 was active in in vivo models of stress urinary incontinence.


Pharmaceutical Research | 2015

Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)

Manthena V. Varma; Stefanus J. Steyn; Charlotte Moira Norfor Allerton; Ayman El-Kattan


Journal of Medicinal Chemistry | 2007

Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.

Mark Edward Bunnage; Julian Blagg; John Steele; Dafydd R. Owen; Charlotte Moira Norfor Allerton; Andrew B. McElroy; Duncan Charles Miller; Tracy J. Ringer; Kenneth John Butcher; Kevin Beaumont; Karen Evans; Andrew J. Gray; Stephen J. Holland; Neil Feeder; Robert S. Moore; David Brown


Archive | 2000

5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors

Charlotte Moira Norfor Allerton; Christopher Gordon Barber; Graham Nigel Maw; David James Rawson


Journal of Medicinal Chemistry | 2006

A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.

Charlotte Moira Norfor Allerton; Christopher Gordon Barber; Kevin Beaumont; David Brown; Susan M. Cole; David Ellis; Charlotte Alice Louise Lane; Graham Nigel Maw; Natalie M. Mount; David James Rawson; Colin Robinson; Stephen Derek Albert Street; Nicholas W. Summerhill


Archive | 2002

Imidazo-triazine derivatives as pde 5 inhibitors

Charlotte Moira Norfor Allerton; Kevin Neil Dack; Mark Ian Kemp


Archive | 2001

Substituted imidazoles as tafia inhibitors

Charlotte Moira Norfor Allerton; Julian Blagg; Mark Edward Bunnage; John Steele


Archive | 2002

Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors

Charlotte Moira Norfor Allerton; Christopher Gordon Barber; Mark Ian Kemp

Collaboration


Dive into the Charlotte Moira Norfor Allerton's collaboration.

Researchain Logo
Decentralizing Knowledge